Reuters

•

0 gostou•902 visualizações

Clare Weeks

Office interiors, Nicosia, Cyprus
Roll-out of TR new identity to
140 sites globally

Office interiors, London, UK
Optimised workplace branding,
design and installation

Office interiors, Barcelona
Flagship news site

Office interiors, Milan
Interior branding for new flagship news site

Mais conteúdo relacionado

Destaque

The Regulatory Policy Institute, based in Oxford, holds an annual conference on competition and regulation. At this year’s conference, OHE’s Jon Sussex described how the prescription medicines market in England is regulated for innovation. The regulatory problem for the pharmaceutical market is different from that for utilities markets, transport, financial services and indeed markets for all other types of goods and services. The source of the regulatory problem for prescription medicines in the NHS is that the consumer (patient) neither decides which medicine is prescribed nor is responsible for paying for it. For other goods and services, the consumer decides and pays, as well as consumes. In the pharmaceutical market under the NHS, it is the payer who effectively decides the value of an innovation, not the patient. The cost and risk in drug development are high. To determine how best to target its R&D efforts, the pharmaceutical industry needs clear signals about what innovation the health care payer, the NHS, values. The recent history of such signalling has been dominated in England by the actions of the National Institute for Health and Care Excellence (NICE), whose assessments also have considerable influence internationally. Moreover, although England represents only 2% of the world pharmaceutical market, its prices are use as a reference for pricing in other markets. How NICE expresses the value of medicines can be viewed as a mean of regulating innovation. NICE always has based its decisions about value on the incremental cost to the tax-funded health and social care services of the additional quality-adjusted life years a new medicine offers to patients. During the last year, NICE has been consulting on ways to broaden its assessment of value, particularly on whether to take account of the burden of disease and wider societal impacts beyond QALYs. The decisions have not yet been made and the signal to potential pharmaceutical innovators remains fuzzy.

Regulating for Innovation in England Sussex 2014

Office of Health Economics

Personalised medicine holds great promised for both improving patients’ outcomes and enhancing the efficiency of treatment. Medicines paired with diagnostics are the backbone of personalised medicine, presenting new challenges in for health technology assessment. The situation in England, particularly how NICE might respond to this challenge, was the focus of the third networking event co-sponsored by the Association of the British Pharmaceutical Industry association (ABPI) and the British In Vitro Diagnostics Association. At this one-day event, speakers set the stage for discussion by presenting defining the context of this challenge for England. OHE’s Adrian Towse presented on the economics. He discussed the elements of value of a diagnostics test (see our earlier blog post) and described the context necessary to produce useful assessments and to ensure subsequent use in the marketplace. His topics included issues of evidence generation, incentives for innovation, flexible approaches to access coincident with evidence development, and encouraging uptake and use.

A Health Economics Perspective on NICE and Stratified Medicine Towse Jan 2014

Office of Health Economics

Health care reforms in England during the last decade have been inﬂuenced by the idea that encouraging competition between hospitals, with nationally ﬁxed prices, will increase the quality of care for patients. Some research has found a positive connection between competition and outcomes. A principal criticism of such studies has been the measures of quality of care that were used. This analysis uses NHS PROMs data, collected both before and after treatment, indicating the extent to which the surgery produces improvement in patients’ self-reported health status. Following an approach common in the literature on competition, hospital market concentration is used as an indicator of competition. Data were collected for 2011–12 for all English NHS hospitals and all elective primary hip replacements. This presentation explains methods and presents results.

Hospital Concentration and Patients Outcomes in the NHS: New Research

Office of Health Economics

APIFARMA, the Portuguese pharmaceutical industry assocation, holds a series of conference throughout they year. OHE's Jorge Mestre-Ferrandiz, an expert on pricing and reimbursement (P&R) in Europe, was the lead speaker at the October 2014 conference on access to innovation. His presentation covers existing and potential approaches to evaluating new medicines as a condition for P&R in France, Germany and the UK.

Approaches to Evaluating New Medicines in France, Germany and England

Office of Health Economics

The Role of HTA for Biosimilars Mestre-Ferrandiz 2014

Office of Health Economics

Aurelio Agostino d'Ippona

LuigiSav95

Regenerative medicine akt_nov14

Office of Health Economics

Each year, the OHE sponsors a lecture that explores a timely issue in medicine or health economics. At the 22nd Annual Lecture, the issues and challenges of universal health care coverage in low- and middle-income countries were presented by Professor Anne Mills of the London School of Hygiene and Tropical Medicine. The audio of this lecture now is available at http://news.ohe.org/2014/08/19/annual-lecture-2014-universal-health-coverage/

Universal Health Coverage: The Holy Grail?

Office of Health Economics

Lena - Amore della mia vita

LuigiSav95

Destaque (9)

Regulating for Innovation in England Sussex 2014

A Health Economics Perspective on NICE and Stratified Medicine Towse Jan 2014

Hospital Concentration and Patients Outcomes in the NHS: New Research

Approaches to Evaluating New Medicines in France, Germany and England

The Role of HTA for Biosimilars Mestre-Ferrandiz 2014

Aurelio Agostino d'Ippona

Regenerative medicine akt_nov14

Universal Health Coverage: The Holy Grail?

Lena - Amore della mia vita

Reuters

1. Office interiors, Nicosia, Cyprus Roll-out of TR new identity to 140 sites globally

2. Office interiors, London, UK Optimised workplace branding, design and installation

3. Office interiors, Barcelona Flagship news site

4. Office interiors, Milan Interior branding for new flagship news site

Reuters

Recomendados

Recomendados

Mais conteúdo relacionado

Destaque

Destaque (9)

Reuters